Back to results
US 10,093,694 B2Granted
Compounds for treating eye disorders or diseases
AssigneesGuangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd., The Regents of the University of California
InventorsRui Hou, Kang Zhang, Gen Li
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that inhibit or prevent protein aggregation, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with protein aggregation.
Claims18
A method of treating an eye disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of Formula (Ic):
- or a pharmaceutically acceptable salt thereof,
- wherein the eye disease or disorder is selected from the group consisting of cataracts, congenital cataracts, cortical opacities, posterior subcapsular cataracts, presbyopia, nuclear sclerosis, retinal degenerative disorder, Refsum disease, Smith-Lemli-Opitz syndrome, Schnyder crystalline corneal dystrophy, drusen, age-related macular degeneration, and diabetic retinopathy;
- and wherein
- X is —C(R4)2—;
- each R4 is independently hydrogen, —ORe, optionally substituted C1-C6alkyl, or halogen;
- each Re is independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6heteroalkyl, optionally substituted C3-C10cycloalkyl, optionally substituted C2-C10heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- Y is —CH2—, or —CH(R5)—;
- R5 is optionally substituted C1-C6alkyl or halogen;
- R6 and R7 are each independently C1-C3alkyl;
- R8 is —ORh, or —N(Ri)2;
- Rh is hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6heteroalkyl, optionally substituted C3-C10cycloalkyl, optionally substituted C2-C10heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- each Ri is independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6heteroalkyl, optionally substituted C3-C10cycloalkyl, optionally substituted C2-C10heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- or two Ri are taken together with the N atom to which they are attached to form an optionally substituted heterocycloalkyl ring;
- R1 is —OR10, —SR10, —N(R10)2, or halogen;
- and each R10 is independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6heteroalkyl, optionally substituted C3-C10cycloalkyl, optionally substituted C2-C10heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
- or two R10 are taken together with the N atom to which they are attached to form an optionally substituted heterocycloalkyl ring.
13 more elements
Dependencies are inferred from the claim text.